deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT04022980

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma

Sponsor: Atrium Health Levine Cancer Institute

Conditions Brain and Nervous System Eye and Orbit
Interventions Nivolumab
Updated 22 times since 2019 Last updated: Dec 26, 2025 Started: Mar 31, 2020 Primary completion: Jan 21, 2025 Completion: Dec 22, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Brain and Nervous System and Eye and Orbit, this trial is completed. The trial is conducted by Atrium Health Levine Cancer Institute and has accumulated 22 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~May 2022 · 6 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~May 2024 · 3 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~May 2025 · 3 months · monthly snapshot~May 2025 – ~Aug 2025 · 3 months · monthly snapshot~Aug 2025 – ~Jan 2026 · 5 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

22 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Aug 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1

  3. May 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1

▶ Show 17 earlier versions

  1. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1

  3. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Oct 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

  6. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

  9. Jul 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  10. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  11. Nov 2021 — May 2022 [monthly]

    Recruiting PHASE1

  12. Jun 2021 — Nov 2021 [monthly]

    Recruiting PHASE1

  13. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  14. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  15. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  16. Feb 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  17. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Atrium Health Levine Cancer Institute
  • Bristol-Myers Squibb
  • Wake Forest University Health Sciences
Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations